CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

CARGO Therapeutics, Inc. Common Stock

NextGen Life Sciences provides solutions in the fields of biotechnology and healthcare by offering testing equipment, reagents, kits, and instruments for medical research.

NextGen Life Sciences

Magazyn E-Commerce is a portal dedicated to the e-commerce industry, providing practical advice and insights for online stores. It features articles prepared by experts and practitioners in the field.

Magazyn E-Commerce

CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies. CARGO is on a mission to outsmart cancer by advancing a new generation of best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. In addition, far too many patients are unable to access these potentially curative therapies due to other challenges, including manufacturing, supply constraints, slow turnaround time and reimbursement hurdles. The team at CARGO is intensely focused on pursuing novel solutions to achieve better cancer treatment outcomes and experiences.

CARGO Therapeutics

Today we announced the appointment of Michael Ports, PhD, as Chief Scientific Officer. In this role at CARGO, Dr. Ports will be responsible for advancing our proprietary platform technologies and discovery-stage programs. Learn more: https://bit.ly/45QfufU

Today at the 8th CAR-TCR Summit in Boston, John Rossi, CARGO’s Vice President and Head of Translational Medicine, is presenting on strategies to deliver next generation engineered CAR T-cell therapy products to overcome resistance. John is also participating in a roundtable discussion on mechanisms of resistance and how to overcome them. Learn more here: https://lnkd.in/dn-KZVN 
#CARTCR #celltherapy #CART

Today we announced the addition of independent directors to our Board of Directors, bringing together an esteemed group of experienced life science leaders with expertise spanning finance, business operations, drug discovery and clinical development, including experts and pioneers in #CART therapies and #oncology. Learn more: https://bit.ly/47KuJIs

At CARGO, we are on a mission to advance next generation #CART therapies – and we are growing! We’re currently searching for a Medical Director to join our team. In this role, you’ll leverage your strong experience working across the clinical team to identify, influence and support priority initiatives while contributing to the leadership team and the advancement of CARGO cell therapy products. Review the job description here: https://lnkd.in/gRZYD2_3
#hiring #biotechjobs #celltherapy


Congratulations to our co-founder Crystal Mackall, MD, who was recently featured in an Endpoints News special report on 20 women reshaping biopharma for her pioneering work in the CAR T-cell therapy and oncology fields and her commitment to advocating for the next generation of women in biopharma! https://bit.ly/45qvyEz 
#CART #celltherapy #oncology

We are thrilled to participate in WuXi AppTec's BOLD: Innovation That Matters online series today! Our CEO Gina Simmons Chapman shares more about our work to advance #CART therapies for cancer during the spotlight session on the next wave of cancer therapeutics. Learn more and tune in here: https://bit.ly/43s85kM #TakingBOLDAction 

Metric
Company Name	CARGO Therapeutics, Inc. Common Stock	NextGen Life Sciences	Magazyn E-Commerce
Symbol	CRGX
MSH ID	COM:CARGO-TX	COM:NEXTGENLIFE	PL:MAGAZYN-ECOMMERCE
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Commercial & Professional Services
Industry	Biotechnology	Biotechnology	E-commerce
Country	US	IN	PL
Stage
Employee Count	123
Website	cargo-tx.com	nextgenlife.com	magazyn-ecommerce.pl
LinkedIn	cargo-tx-inc		magazyn-ewp
Founders

Metric
Market Cap	761.31M
Enterprise Value
Monthly Web Traffic		1.52K
Web Traffic Growth		1.11
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CRGX

COM:CARGO-TX

CARGO Therapeutics

Last Close

15.73

22/11 21:00

Market Cap

761.31M

Beta: -

Volume Today

156.59K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue